Establishment and characterization of a new cell line, FPS-1, derived from human undifferentiated pleomorphic sarcoma, overexpressing epidermal growth factor receptor and cyclooxygenase-2

Anticancer Research

Volumn 26, Issue 5 A, 2006, Pages 3393-3401

  Hakozaki, Michiyuki ^a   Hojo, Hiroshi ^a   Sato, Michiko ^a   Tajino, Takahiro ^a   Yamada, Hitoshi ^a   Kikuchi, Shinichi ^a   Abe, Masafumi ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cyclooxygenase 2 (COX 2); Epidermal growth factor receptor (EGFR); FPS 1 cell line; Malignant fibrous histiocytoma (MFH); p53 gene; Sarcoma; Undifferentiated pleomorphic sarcoma

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER CELL; CYTOGENETICS; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; PRIORITY JOURNAL; SOFT TISSUE SARCOMA;

AGED; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CYCLOOXYGENASE 2; HUMANS; KARYOTYPING; MALE; MEMBRANE PROTEINS; MICE; MICE, NUDE; MICE, SCID; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SARCOMA; SOFT TISSUE NEOPLASMS; STOMACH NEOPLASMS;

EID: 33750699263     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Fletcher CDM, van den Berg E and Molenaar WM: Pleomorphic malignant fibrous histiocytoma/undifferentiated high grade pleomorphic sarcoma. In: World Health Organization Classification of Tumours; Tumours of Soft Tissue and Bone. Fletcher CDM, Unni KK and Mertens F (eds.). Lyon, IARC Press, pp. 120-122, 2002.
2. Weiss SW and Goldblum JR: Malignant fibrohistiocytic tumors. In: Enzinger and Weiss's Soft Tissue Tumors. 4th edition. Weiss SW and Goldblum JR (eds.). St. Louis, Mosby, pp. 535-569, 2001.
3. Hecht F, Berger C, Hecht BK and Speiser BL: Fibrous histiocytoma cell line: chromosome studies of mouse and man. Cancer Genet Cytogenet 8: 359-362, 1983.
4. Shirasuna K, Sugiyama M and Miyazaki T: Establishment and characterization of neoplastic cells from a malignant fibrous histiocytoma. A possible stem cell line. Cancer 55: 2521-2532, 1985.
5. Roholl PJ, Kleyne J, Van Blokland M, Spies PL, Rutgers DH, Albus-Lutter CE and Van Unnik JA: Characterization of two cell lines, derived from two malignant fibrous histiocytomas. J Pathol 750: 103-112, 1986.
6. Iwasaki H, Isayama T, Ohjimi Y, Kikuchi M, Yoh S, Shinohara N, Yoshitake K, Ishiguro M, Kamada N and Enjoji M: Malignant fibrous histiocytoma. A tumor of facultative histiocytes showing mesenchymal differentiation in cultured cell lines. Cancer 69: 437-447, 1992.
7. Takahashi K and Sato K: Establishment and characterization of a human neoplastic cell line (MFH-ino) derived from malignant fibrous histiocytoma of maxilla. Hum Cell 4: 51-57, 1991.
8. Kanzaki T, Kitajima S and Suzumori K: Biological behavior of cloned cells of human malignant fibrous histiocytoma in vivo and in vitro. Cancer Res 51: 2133-2137, 1991.
9. Roholl PJ, Prinsen I, Rademakers LP, Hsu SM and Van Unnik JA: Two cell lines with epithelial cell-like characteristics established from malignant fibrous histiocytomas. Cancer 68: 1963-1972, 1991.
10. Sekiguchi M, Asanuma K, Shiroko Y, Mori S, Shimoda T and Kamada N: Biological characteristics of a continuous cultured cell line derived from a human malignant fibrous histiocytoma. Hum Cell 7: 199-206, 1994.
11. Yonemoto T, Takenouchi T, Tokita H, Tatezaki S, Mukaida N, Mikata A and Moriya H: Establishment and characterization of a human malignant fibrous histiocytoma cell line. Clin Orthop Relat Res 320: 159-167, 1995.
12. Yokota T, Ishizaki R, Ohishi H and Ohami H: Establishment and characterization of a fibrous histiocytoma cell line (NMSG 10) derived from a malignant fibrous histiocytoma. Pathol Res Pract 191: 1231-1238, 1995.
13. Krause AK, Hinrichs SH, Orndal C, DeBoer J, Neff JR and Bridge JA: Characterization of a human myxoid malignant fibrous histiocytoma cell line, OH931. Cancer Genet Cytogenet 94: 138-143, 1997.
14. Reinecke P, Moll R, Hildebrandt B, Schmitz M, Schneider EM, Koldovsky P, Schardt C, Gabbert HE and Gerharz C: A novel human malignant fibrous histiocytoma cell line of the heart (MFH-H) with secretion of hematopoietic growth factors. Anticancer Res 19: 1901-1907, 1999.
15. Endo K, Sakatani T, Watanabe M, Yoshida H, Nanba E and Ito H: Wild-type p53 gene transfer resulted in cell cycle arrest, but not apoptosis of newly established human malignant fibrous histiocytoma cell line. Int J Oncol 15: 935-942, 1999.
16. Mairal A, Chibon F, Rousselet A, Couturier J, Terrier P and Aurias A: Establishment of a human malignant fibrous histiocytoma cell line, COMA. Characterization by conventional cytogenetics, comparative genomic hybridization, and multiplex fluorescence in situ hybridization. Cancer Genet Cytogenet 121: 117-123, 2000.
17. Kiyozuka Y, Nakagawa H, Uemura Y, Senzaki H, Yamamoto A, Noguchi T, Mizuta H, Nakanishi K, Nakano S and Tsubura A: Novel cell lines established from a human myxoid malignant fibrous histiocytoma arising in the uterus. Cancer Genet Cytogenet 727: 7-15, 2001.
18. Mori A, Tagawa T, Kamei T, Murata T, Inui M and Ohse S: Characterization of four cell lines derived from a human malignant fibrous histiocytoma of the maxillary sinus. Oral Oncol 37: 527-536, 2001.
19. Nakatani T, Marui T, Yamamoto T, Kurosaka M, Akisue T and Matsumoto K: Establishment and characterization of cell line TNMY1 derived from human malignant fibrous histiocytoma. Pathol Int 57: 595-602, 2001.
20. Fang Z, Mukai H, Nomura K, Shinomiya K, Matsumoto S, Kawaguchi N, Kitagawa T and Kanda H: Establishment and characterization of a cell line from a malignant fibrous histiocytoma of bone developing in a patient with multiple fibrous dysplasia. J Cancer Res Clin Oncol 128: 45-49, 2002.
21. Nishio J, Iwasaki H, Ishiguro M, Ohjimi Y, Nishimura N, Koga T, Kawarabayashi T, Kaneko Y and Kikuchi M: Establishment of a new human malignant fibrous histiocytoma cell line, FU-MFH-1: cytogenetic characterization by comparative genomic hybridization and fluorescence in situ hybridization. Cancer Genet Cytogenet 144: 44-51, 2003.
22. Murakami Y, Hayashi K and Sekiya T: Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis. Cancer Res 57: 3356-3361, 1991.
23. Kuze T, Nakamura N, Hashimoto Y, Hojo H, Abe M and Wakasa H: The relationship between the gene mutation of p53 and the protein expression of p53 and Ki-67 in non-Hodgkin's lymphomas. Pathol Int 46: 130-136, 1996.
24. Hashimoto Y, Nakamura N, Kuze T, Abe M and Wakasa H: Intranuclear expression of cyclin D1 protein as a useful prognostic marker for mantle cell lymphoma. Fukushima J Med Sci 43: 87-98, 1997.
25. Narita T, Taga T, Sugita K, Nakazawa S and Ohta S: The autocrine loop of epidermal growth factor receptor-epidermal growth factor/transforming growth factor-alpha in malignant rhabdoid tumor cell lines: heterogeneity of autocrine mechanism in TTC549. Jpn J Cancer Res 92: 269-278, 2001.
26. Yuan A, Yu CJ, Shun CT, Luh KT, Kuo SH, Lee YC and Yang PC: Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer 115: 545-555, 2005.
27. Hakozaki M, Hojo H, Sato M, Kaneko Y, Watanabe N, Kikuchi S and Abe M: Establishment and characterization of a new cell line, FRTK-1, derived from human malignant rhabdoid tumor of the kidney, with over expression of epidermal growth factor receptor and cyclooxygenase-2. Oncol Rep 16: 265-271, 2006.
28. Toguchida J, Yamaguchi T, Ritchie B, Beauchamp RL, Dayton SH, Herrera GE, Yamamuro T, Kotoura Y, Sasaki MS, Little JB, Weichselbaum RR, Ishizaki K and Yandell DW: Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 52: 6194-6199, 1992.
29. Yoo J, Lee HK, Kang CS, Park WS, Lee JY and Shim SI: p53 gene mutations and p53 protein expression in human soft tissue sarcomas. Arch Pathol Lab Med 121: 395-399, 1997.
30. Molina P, Pellin A, Navarro S, Boix J, Carda C and Llombart-Bosch A: Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance. Virchows Arch 435: 596-605, 1999.
31. Davidoff AM, Pence JC, Shorter NA, Iglehart JD and Marks JR: Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene 7: 127-133, 1992.
32. Villuendas R, Piris MA, Algara P, Sanchez-Beato M, Sanchez-Verde L, Martinez JC, Orradre JL, Garcia P, Lopez C and Martinez P: The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood 82: 3151-3156, 1993.
33. Lepelley P, Preudhomme C, Vanrumbeke M, Quesnel B, Cosson A and Fenaux P: Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia 8: 1342-1349, 1994.
34. Nicholson RI, Gee JM and Harper ME: EGFR and cancer prognosis. Eur J Cancer 37: S9-15, 2001.
35. Holbro T, Civenni G and Hynes NE: The ErbB receptors and their role in cancer progression. Exp Cell Res 284: 99-110, 2003.
36. Dobashi Y, Takei N, Suzuki S, Yoneyama H, Hanawa M and Ooi A: Aberration of epidermal growth factor receptor expression in bone and soft-tissue tumors: protein overexpression, gene amplification and activation of downstream molecules. Mod Pathol 17: 1497-1505, 2004.
37. Yamamoto T, Fujita I, Akisue T, Marui T, Nakatani T, Kawamoto T, Hitora T, Nagira K, Matsumoto K and Kurosaka M: Amphiregulin and epidermal growth factor receptor expression in human malignant fibrous histiocytoma of soft tissues. Anticancer Res 24: 1307-1310, 2004.
38. Yamamoto T, Akisue T, Marui T, Nakatani T, Kawamoto T, Hitora T, Nagira K, Fujita I, Matsumoto K and Kurosaka M: Expression of betacellulin, heparin-binding epidermal growth factor and epiregulin in human malignant fibrous histiocytoma. Anticancer Res 24: 2007-2010, 2004.
39. Beech D, Pollock RE, Tsan R and Radinsky R: Epidermal growth factor receptor and insulin-like growth factor-I receptor expression and function in human soft-tissue sarcoma cells. Int J Oncol 12: 329-336, 1998.
40. Abdiu A, Walz TM, Nishikawa BK, Wingren S, Larsson SE and Wasteson A: Human malignant fibrous histiocytomas in vitro: growth characteristics and their association with expression of mRNA for platelet-derived growth factor, transforming growth factor-alpha and their receptors. Eur J Cancer 34: 2094-2100, 1998.
41. Vane JR, Bakhle YS and Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97-120, 1998.
42. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB and Lipsky PE: Cyclooxygenase in biology and disease. FASEB J 12: 1063-1073, 1998.
43. Gately S and Li WW: Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 31: 2-11, 2004.
44. Dickens DS and Cripe TP: Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts. J Pediatr Hematol Oncol 25: 709-714, 2003.
45. Yamashita H, Osaki M, Ardyanto TD, Osaki M, Yoshida H and Ito H: Cyclooxygenase-2 in human malignant fibrous histiocytoma: correlations with intratumoral microvessel density, expression of vascular endothelial growth factor and thymidine phosphorylase. Int J Mol Med 14: 565-570, 2004.
46. Lassus P, Ristimaki A, Huuhtanen R, Tukiainen E, Asko-Seljavaara S, Andersson LC, Miettinen M, Blomqvist C, Haglund C and Bohling T: Cyclooxygenase-2 expression in human soft-tissue sarcomas is related to epithelial differentiation. Anticancer Res 25: 2669-2674, 2005.
47. Yamashita H, Osaki M, Honjo S, Yoshida H, Teshima R and Ito H: A selective cyclooxygenase-2 inhibitor, NS-398, inhibits cell growth by cell cycle arrest in a human malignant fibrous histiocytoma cell line. Anticancer Res 23: 4671-4676, 2003.
48. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K and DuBois RN: Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23: 254-266, 2005.
49. Lippman SM, Gibson N, Subbaramaiah K and Dannenberg AJ: Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways. Clin Cancer Res 11: 6097-6099, 2005.
50. Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR and Ciardiello F: Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 9: 1566-1572, 2003.
51. Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR and Shin DM: Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 10: 5930-5939, 2004.
52. Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS, Shin HJ, Chen A, Khuri FR and Shin DM: Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 11: 6261-6269, 2005.
53. Melisi D, Caputo R, Damiano V, Bianco R, Veneziani BM, Bianco AR, De Placido S, Ciardiello F and Tortora G: Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer 12: 1051-1058, 2005.